1. Scrip

Newron STARS Fade With Sarizotan Failure

Stock Sinks Over 70%

 
• By Kevin Grogan

Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.

Decreasing_Graph
Bad day on the markets for Newron • Source: Shutterstock

Shares in Newron Pharmaceuticals SPA have been battered after the Italian drugmaker revealed that its Rett syndrome drug sarizotan has failed a Phase III trial in patients with the severe neurodevelopmental disorder.

The company has presented top-line results from the STARS study which show that sarizotan failed to hit its primary endpoint – a reduction in episodes of apnea during waking time compared with placebo – and no secondary endpoints were met either

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.